Trials / Completed
CompletedNCT03814291
A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration
A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI302 in Patients With Wet Age-related Macular Degeneration (AMD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single intravitreal injection of IBI302 in patients with wet AMD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IBI302 | 0.05mg/eye;Intraocular injection |
| DRUG | IBI302 | 0.15mg/eye;Intraocular injection |
| DRUG | IBI302 | 0.5mg/eye;Intraocular injection |
| DRUG | IBI302 | 1mg/eye;Intraocular injection |
| DRUG | IBI302 | 2mg/eye;Intraocular injection |
| DRUG | IBI302 | 4mg/eye;Intraocular injection |
Timeline
- Start date
- 2019-04-15
- Primary completion
- 2020-03-05
- Completion
- 2020-04-10
- First posted
- 2019-01-24
- Last updated
- 2025-04-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03814291. Inclusion in this directory is not an endorsement.